Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica

Autores:: De La Hoz, Franklin José Espitia

Tipo de recurso:: Article of journal

Fecha de publicación:: 2022

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_078d4fcd227751f2f3f2645472767348
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/14761
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica
dc.title.translated.eng.fl_str_mv	Influence of tibolone on sexual function and cardiovascular safety in postmenopausal women
title	Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica
spellingShingle	Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica Menopause Hormones Sexuality Effectivenes Safety Cardiovascular diseases Menopausia Hormonas Sexualidad Efectividad Seguridad Enfermedades Cardiovasculares
title_short	Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica
title_full	Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica
title_fullStr	Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica
title_full_unstemmed	Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica
title_sort	Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica
dc.creator.fl_str_mv	De La Hoz, Franklin José Espitia
dc.contributor.author.spa.fl_str_mv	De La Hoz, Franklin José Espitia
dc.subject.eng.fl_str_mv	Menopause Hormones Sexuality Effectivenes Safety Cardiovascular diseases
topic	Menopause Hormones Sexuality Effectivenes Safety Cardiovascular diseases Menopausia Hormonas Sexualidad Efectividad Seguridad Enfermedades Cardiovasculares
dc.subject.spa.fl_str_mv	Menopausia Hormonas Sexualidad Efectividad Seguridad Enfermedades Cardiovasculares
publishDate	2022
dc.date.accessioned.none.fl_str_mv	2022-01-14 00:00:00
dc.date.available.none.fl_str_mv	2022-01-14 00:00:00
dc.date.issued.none.fl_str_mv	2022-01-14
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_dcae04bc http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ARTREV
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2022-3223
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2022-3223
identifier_str_mv	2215-7840 10.32997/rcb-2022-3223 2389-7252
url	https://doi.org/10.32997/rcb-2022-3223
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3223/3088
dc.relation.citationedition.spa.fl_str_mv	Núm. 1 , Año 2022
dc.relation.citationendpage.none.fl_str_mv	79
dc.relation.citationissue.spa.fl_str_mv	1
dc.relation.citationstartpage.none.fl_str_mv	66
dc.relation.citationvolume.spa.fl_str_mv	11
dc.relation.references.spa.fl_str_mv	Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993; 168(3 Pt 1):772-80. http://dx.doi.org/10.1016/s0002-9378(12)90817-0 Jenabi E, Shobeiri F, Hazavehei SM, Roshanaei G. Assessment of Questionnaire Measuring Quality of Life in Menopausal Women: A Systematic Review. Oman Med J. 2015; 30(3):151-6. http://dx.doi.org/10.5001/omj.2015.34 Li C, Samsioe G, Borgfeldt C, Lidfeldt J, Agardh CD, Nerbrand C. Menopause-related symptoms: what are the background factors? A prospective population-based cohort study of Swedish women (The Women's Health in Lund Area study). Am J Obstet Gynecol. 2003; 189(6):1646-53. http://dx.doi.org/10.1016/s0002-9378(03)00872-x Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am. 2011; 38(3):489-501. http://dx.doi.org/10.1016/j.ogc.2011.05.006 Espitia De la Hoz FJ. Prevalence of genitourinary syndrome of menopause and impact on sexuality of women in Quindío (Colombia), 2013-2016. Rev Colomb Obstet Ginecol. 2018; 69(4):249-59. https://doi.org/10.18597/rcog.3111 Warren MP, Halpert S. Hormone replacement therapy: controversies, pros and cons. Best Pract Res Clin Endocrinol Metab. 2004; 18(3):317-32. https://doi.org/10.1016/j.beem.2004.02.005 Björn I, Bäckström T, Lalos A, Sundström-Poromaa I. Adverse mood effects during postmenopausal hormone treatment in relation to personality traits. Climacteric. 2006; 9(4):290-7. https://doi.org/10.1080/13697130600865766 Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001; 75(6):1065-79. https://doi.org/10.1016/s0015-0282(01)01791-5 Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecol Oncol. 2016; 140(1):101-6. https://doi.org/10.1016/j.ygyno.2015.11.016 Hodis HN, Mack WJ. Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol. 2014; 142:68-75. https://doi.org/10.1016/j.jsbmb.2013.06.011 The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7):728-53. https://doi.org/10.1097/GME.0000000000000921 Preston RA. Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. Climacteric. 2009; 12 Suppl 1:66-70. https://doi.org/10.1080/13697130902775788 Kenemans P. Tibolone: how does its mechanism of action translate into clinical effects. Maturitas. 2004; 48 Suppl 1:S1-3. https://doi.org/10.1016/j.maturitas.2004.02.014 Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast. Taiwan J Obstet Gynecol. 2007; 46(2):127-34. https://doi.org/10.1016/S1028-4559(07)60006-0 Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002; 87(1):16-23. https://doi.org/10.1210/jcem.87.1.8141 Timmer CJ, Verheul HA, Doorstam DP. Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol. 2002; 54(2):101-6. https://doi.org/10.1046/j.1365-2125.2002.01619.x Crona N, Samsioe G, Lindberg UB, Silfverstolpe G. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas. 1988; 9(4):303-8. https://doi.org/10.1016/0378-5122(88)90095-3 Kicovic PM, Cortés-Prieto J, Luisi M, Milojevic S, Franchi F. Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduccion. 1982; 6(2):81-91. Punnonen R, Liukko P, Cortes-Prieto J, Eydam F, Milojevic S, Trévoux R, et al. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women. Maturitas. 1984; 5(4):281-6. https://doi.org/10.1016/0378-5122(84)90023-9 de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids. 2003; 68(1):21-30. https://doi.org/10.1016/s0039-128x(02)00112-5 Jelinek J, Kappen A, Schönbaum E, Lomax P. A primate model of human postmenopausal hot flushes. J Clin Endocrinol Metab. 1984; 59(6):1224-8. https://doi.org/10.1210/jcem-59-6-1224 Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas. 2005; 50(3):222-30. https://doi.org/10.1016/j.maturitas.2004.06.001 Espitia De La Hoz FJ. Terapia de reemplazo hormonal combinada con testosterona para el tratamiento del trastorno del deseo sexual hipoactivo en mujeres en climaterio. Arch Med (Manizales) 2020; 20(1):71-85. https://doi.org/10.30554/archmed.20.1.3388.2020 Verheul HA, Blok LJ, Burger CW, Hanifi-Moghaddam P, Kloosterboer HJ. Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate. Reprod Sci. 2007; 14(2):160-8. https://doi.org/10.1177/1933719106298684 Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas. 1998; 30(3):295-305. https://doi.org/10.1016/s0378-5122(98)00059-0 Formoso G, Perrone E, Maltoni S, Balduzzi S, D'Amico R, Bassi C, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2012; (2):CD008536. https://doi.org/10.1002/14651858.CD008536.pub2 Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol. 1999; 106 Suppl 19:1-21. Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric. 2010; 13(2):147-56. https://doi.org/10.1080/13697130903009195 Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. The in vivo human metabolism of tibolone. Drug Metab Dispos. 2002; 30(2):106-12. https://doi.org/10.1124/dmd.30.2.106 Palacios S, Menendez C, Jurado AR, Castaño R, Vargas JC. Changes in sex behaviour after menopause: effects of tibolone. Maturitas. 1995; 22(2):155-61. https://doi.org/10.1016/0378-5122(95)00930-j Kökçü A, Cetinkaya MB, Yanik F, Alper T, Malatyalioğlu E. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas. 2000; 36(1):75-80. https://doi.org/10.1016/s0378-5122(00)00134-1 Omu F, Elbiaa A, Ghafour A, Gadalla I, Omu A. Beneficial Effects of Tibolone on Sexual Dys-function in Women with Premature Ovarian Failure (POF). Health. 2016; 8(9):857-67. https://doi.org/10.4236/health.2016.89090 Dören M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril. 2001; 75(3):554-9. https://doi.org/10.1016/s0015-0282(00)01768-4 van der Stege JG, Groen H, van Zadelhoff SJ, Lambalk CB, Braat DD, van Kasteren YM, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008; 15(1):23-31. https://doi.org/10.1097/gme.0b013e3180f6108c Drillich A, Davis SR. Androgen therapy in women: what we think we know. Exp Gerontol. 2007; 42(6):457-62. https://doi.org/10.1016/j.exger.2007.02.005 Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001; 76(1-5):231-8. https://doi.org/10.1016/s0960-0760(01)00044-9 Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric. 2001; 4(1):28-41. Wu MH, Pan HA, Wang ST, Hsu CC, Chang FM, Huang KE. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric. 2001; 4(4):314-9. Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril. 2004; 81(3):617-23. https://doi.org/10.1016/j.fertnstert.2003.07.041 Wender MC, Edelweiss MI, Campos LS, de Castro JA, Spritzer PM. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause. 2004; 11(4):423-9. https://doi.org/10.1097/01.gme.0000109315.11228.ac Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005; 51(1):21-8. https://doi.org/10.1016/j.maturitas.2005.02.011 Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int. 2002; 13(3):241-8. https://doi.org/10.1007/s001980200021 Lippuner K, Haenggi W, Birkhaeuser MH, Casez JP, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. J Bone Miner Res. 1997; 12(5):806-12. https://doi.org/10.1359/jbmr.1997.12.5.806 Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric. 2002; 5(4):390-8. Morris EP, Denton ER, Robinson J, MacDonald LM, Rymer JM. High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure. Climacteric. 1999; 2(1):13-20. https://doi.org/10.3109/13697139909025558 Cagnacci A, Baldassari F, Arangino S, Alessandrini C, Volpe A. Administration of tibolone decreases 24 h heart rate but not blood pressure of post-menopausal women. Maturitas. 2004; 48(2):155-60. https://doi.org/10.1016/j.maturitas.2003.08.011 Ostberg JE, Damjanovic T, Dimkovic N, Byrne D, Mikhailidis DP, Prelevic GM. Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. Fertil Steril. 2004; 81(6):1624-31. https://doi.org/10.1016/j.fertnstert.2003.11.033 Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women. Gynecol Endocrinol. 2004; 18(5):244-57. https://doi.org/10.1080/09513590410001715207 Vassalle C, Cicinelli E, Lello S, Mercuri A, Battaglia D, Maffei S. Effects of menopause and tibolone on different cardiovascular biomarkers in healthy women. Gynecol Endocrinol. 2011; 27(3):163-9. https://doi.org/10.3109/09513590.2010.488770. von Eckardstein A, Schmiddem K, Hövels A, Gülbahçe E, Schuler-Lüttmann S, Elbers J, et al. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis. 2001; 159(2):433-9. https://doi.org/10.1016/s0021-9150(01)00522-6 Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Garibaldi S, et al. Tibolone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrinol Metab. 2004; 89(9):4594-600. https://doi.org/10.1210/jc.2003-032189. Cicinelli E, Ignarro LJ, Galantino P, Pinto V, Barba B, Schonauer S. Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertil Steril. 2002; 78(3):464-8. https://doi.org/10.1016/s0015-0282(02)03295-8 Simoncini T, Genazzani AR. Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells. Mol Cell Endocrinol. 2000; 162(1-2):87-94. https://doi.org/10.1016/s0303-7207(00)00206-9 Aguayo-Cerón KA, Morales-González JA, Gutiérrez-Iglesias G, Parra-Barrera A, Jiménez-Zamarripa CA, Ocharán-Hernández ME, et al. Efecto Regulador de Tibolona sobre la Actividad Antiinflamatoria del Macrófago. Revista Mexicana De Ingeniería Biomédica. 2019; 40(3):1-10. https://doi.org/10.17488/RMIB.40.3.1 North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012; 19(3):257-71. https://doi.org/10.1097/gme.0b013e31824b970a Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(11):3975-4011. https://doi.org/10.1210/jc.2015-2236 Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas. 2006; 55(3):278-87. https://doi.org/10.1016/j.maturitas.2006.04.012 Appt SE, Törmälä R, Franke AA, Mikkola TS, Tikkanen MJ, Ylikorkala O, et al. Soy-tibolone combination - effect on lipids in postmenopausal monkeys and women. Maturitas. 2008; 60(3-4):216-22. https://doi.org/10.1016/j.maturitas.2008.06.003 Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab. 1997; 82(6):1752-6. https://doi.org/10.1210/jcem.82.6.3995 Register TC, Wagner JD, Zhang L, Hall J, Clarkson TB. Effects of tibolone and conventional hormone replacement therapies on arterial and hepatic cholesterol accumulation and on circulating endothelin-1, vascular cell adhesion molecule-1, and E-selectin in surgically menopausal monkeys. Menopause. 2002; 9(6):411-21. https://doi.org/10.1097/00042192-200211000-00006 Stark J, Varbiro S, Sipos M, Tulassay Z, Sara L, Adler I, et al. Antioxidant effect of the active metabolites of tibolone. Gynecol Endocrinol. 2015; 31(1):31-5. https://doi.org/10.3109/09513590.2014.943727 Dubey RK, Gillespie DG, Grögli M, Kloosterboer HJ, Imthurn B. Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors. J Clin Endocrinol Metab. 2004; 89(2):852-9. https://doi.org/10.1210/jc.2003-031272 Castelo-Branco C, Casals E, Figueras F, Sanjuan A, Vicente JJ, Balasch J, et al. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause. 1999 Summer; 6(2):92-7. Nathorst-Böös J, Hammar M. Effect on sexual life--a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas. 1997; 26(1):15-20. https://doi.org/10.1016/s0378-5122(96)01069-9 Espitia De La Hoz FJ, Marega O, Orozco Gallego H. Manejo farmacológico de la disfunción sexual femenina en la postmenopausia, con tibolona y testosterona. Revista de Sexología. 2016; 5(2):9-18. Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, Helmond FA, Van Lunsen RH, Palacios S, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med. 2008; 5(3):646-56. https://doi.org/10.1111/j.1743-6109.2007.00726.x Baños G, Guarner V, Pérez-Torres I. Sex steroid hormones, cardiovascular diseases and the metabolic syndrome. Cardiovasc Hematol Agents Med Chem. 2011; 9(3):137-46. https://doi.org/10.2174/187152511797037547 Kotani K, Sahebkar A, Serban C, Andrica F, Toth PP, Jones SR, et al. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis. 2015; 242(1):87-96. https://doi.org/10.1016/j.atherosclerosis.2015.06.056 Parkin DE, Smith D, Al Azzawi F, Lindsay R, Hart DM. Effects of long-term Org OD 14 administration on blood coagulation in climacteric women. Maturitas. 1987; 9(1):95-101. https://doi.org/10.1016/0378-5122(87)90057-0 Tax L, Kicovic PM. Clinical profile of Org OD14. Maturitas 1984; 6:196. Yates RW, Richards A, McEwan HP, Coutts JR, Walker ID, Davidson JF. Hormonal and fibrinolytic effects of the synthetic steroid Org OD14 in menopausal women. Maturitas 1984; 6:210. Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007; 92(3):911-8. https://doi.org/10.1210/jc.2006-2207. Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res. 2012; 14(1):R13. https://doi.org/10.1186/bcr3097. Bringer J, Raingeard I, Lefebre P, Renard E. Ménopause. Vers un traitement «a la carte». Ann Endocrinol. 2003; 64:337-44. McKinney KA, Thompson W. A practical guide to prescribing hormone replacement therapy. Drugs. 1998; 56:49-57. Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol. 2003; 188(1):286-93. https://doi.org/10.1067/mob.2003.117
dc.rights.spa.fl_str_mv	Franklin José Espitia De La Hoz - 2022
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Franklin José Espitia De La Hoz - 2022 https://creativecommons.org/licenses/by-nc-sa/4.0 http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3223
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstreams/cedf69e9-54d6-4e2f-a312-b82dff0daabf/download
bitstream.checksum.fl_str_mv	5e41eb756c7d0940cc4916f2a6e0759c
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1828230235751972864
spelling	De La Hoz, Franklin José Espitia2022-01-14 00:00:002022-01-14 00:00:002022-01-142215-784010.32997/rcb-2022-32232389-7252https://doi.org/10.32997/rcb-2022-3223application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3223/3088Núm. 1 , Año 20227916611Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol. 1993; 168(3 Pt 1):772-80. http://dx.doi.org/10.1016/s0002-9378(12)90817-0Jenabi E, Shobeiri F, Hazavehei SM, Roshanaei G. Assessment of Questionnaire Measuring Quality of Life in Menopausal Women: A Systematic Review. Oman Med J. 2015; 30(3):151-6. http://dx.doi.org/10.5001/omj.2015.34Li C, Samsioe G, Borgfeldt C, Lidfeldt J, Agardh CD, Nerbrand C. Menopause-related symptoms: what are the background factors? A prospective population-based cohort study of Swedish women (The Women's Health in Lund Area study). Am J Obstet Gynecol. 2003; 189(6):1646-53. http://dx.doi.org/10.1016/s0002-9378(03)00872-xThurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am. 2011; 38(3):489-501. http://dx.doi.org/10.1016/j.ogc.2011.05.006Espitia De la Hoz FJ. Prevalence of genitourinary syndrome of menopause and impact on sexuality of women in Quindío (Colombia), 2013-2016. Rev Colomb Obstet Ginecol. 2018; 69(4):249-59. https://doi.org/10.18597/rcog.3111Warren MP, Halpert S. Hormone replacement therapy: controversies, pros and cons. Best Pract Res Clin Endocrinol Metab. 2004; 18(3):317-32. https://doi.org/10.1016/j.beem.2004.02.005Björn I, Bäckström T, Lalos A, Sundström-Poromaa I. Adverse mood effects during postmenopausal hormone treatment in relation to personality traits. Climacteric. 2006; 9(4):290-7. https://doi.org/10.1080/13697130600865766Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001; 75(6):1065-79. https://doi.org/10.1016/s0015-0282(01)01791-5Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecol Oncol. 2016; 140(1):101-6. https://doi.org/10.1016/j.ygyno.2015.11.016Hodis HN, Mack WJ. Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol. 2014; 142:68-75. https://doi.org/10.1016/j.jsbmb.2013.06.011The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7):728-53. https://doi.org/10.1097/GME.0000000000000921Preston RA. Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. Climacteric. 2009; 12 Suppl 1:66-70. https://doi.org/10.1080/13697130902775788Kenemans P. Tibolone: how does its mechanism of action translate into clinical effects. Maturitas. 2004; 48 Suppl 1:S1-3. https://doi.org/10.1016/j.maturitas.2004.02.014Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast. Taiwan J Obstet Gynecol. 2007; 46(2):127-34. https://doi.org/10.1016/S1028-4559(07)60006-0Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002; 87(1):16-23. https://doi.org/10.1210/jcem.87.1.8141Timmer CJ, Verheul HA, Doorstam DP. Pharmacokinetics of tibolone in early and late postmenopausal women. Br J Clin Pharmacol. 2002; 54(2):101-6. https://doi.org/10.1046/j.1365-2125.2002.01619.xCrona N, Samsioe G, Lindberg UB, Silfverstolpe G. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas. 1988; 9(4):303-8. https://doi.org/10.1016/0378-5122(88)90095-3Kicovic PM, Cortés-Prieto J, Luisi M, Milojevic S, Franchi F. Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduccion. 1982; 6(2):81-91.Punnonen R, Liukko P, Cortes-Prieto J, Eydam F, Milojevic S, Trévoux R, et al. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women. Maturitas. 1984; 5(4):281-6. https://doi.org/10.1016/0378-5122(84)90023-9de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids. 2003; 68(1):21-30. https://doi.org/10.1016/s0039-128x(02)00112-5Jelinek J, Kappen A, Schönbaum E, Lomax P. A primate model of human postmenopausal hot flushes. J Clin Endocrinol Metab. 1984; 59(6):1224-8. https://doi.org/10.1210/jcem-59-6-1224Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas. 2005; 50(3):222-30. https://doi.org/10.1016/j.maturitas.2004.06.001Espitia De La Hoz FJ. Terapia de reemplazo hormonal combinada con testosterona para el tratamiento del trastorno del deseo sexual hipoactivo en mujeres en climaterio. Arch Med (Manizales) 2020; 20(1):71-85. https://doi.org/10.30554/archmed.20.1.3388.2020Verheul HA, Blok LJ, Burger CW, Hanifi-Moghaddam P, Kloosterboer HJ. Levels of tibolone and estradiol and their nonsulfated and sulfated metabolites in serum, myometrium, and vagina of postmenopausal women following treatment for 21 days with tibolone, estradiol, or estradiol plus medroxyprogestrone acetate. Reprod Sci. 2007; 14(2):160-8. https://doi.org/10.1177/1933719106298684Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas. 1998; 30(3):295-305. https://doi.org/10.1016/s0378-5122(98)00059-0Formoso G, Perrone E, Maltoni S, Balduzzi S, D'Amico R, Bassi C, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2012; (2):CD008536. https://doi.org/10.1002/14651858.CD008536.pub2Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol. 1999; 106 Suppl 19:1-21.Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric. 2010; 13(2):147-56. https://doi.org/10.1080/13697130903009195Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. The in vivo human metabolism of tibolone. Drug Metab Dispos. 2002; 30(2):106-12. https://doi.org/10.1124/dmd.30.2.106Palacios S, Menendez C, Jurado AR, Castaño R, Vargas JC. Changes in sex behaviour after menopause: effects of tibolone. Maturitas. 1995; 22(2):155-61. https://doi.org/10.1016/0378-5122(95)00930-jKökçü A, Cetinkaya MB, Yanik F, Alper T, Malatyalioğlu E. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas. 2000; 36(1):75-80. https://doi.org/10.1016/s0378-5122(00)00134-1Omu F, Elbiaa A, Ghafour A, Gadalla I, Omu A. Beneficial Effects of Tibolone on Sexual Dys-function in Women with Premature Ovarian Failure (POF). Health. 2016; 8(9):857-67. https://doi.org/10.4236/health.2016.89090Dören M, Rübig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril. 2001; 75(3):554-9. https://doi.org/10.1016/s0015-0282(00)01768-4van der Stege JG, Groen H, van Zadelhoff SJ, Lambalk CB, Braat DD, van Kasteren YM, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008; 15(1):23-31. https://doi.org/10.1097/gme.0b013e3180f6108cDrillich A, Davis SR. Androgen therapy in women: what we think we know. Exp Gerontol. 2007; 42(6):457-62. https://doi.org/10.1016/j.exger.2007.02.005Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001; 76(1-5):231-8. https://doi.org/10.1016/s0960-0760(01)00044-9Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric. 2001; 4(1):28-41.Wu MH, Pan HA, Wang ST, Hsu CC, Chang FM, Huang KE. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric. 2001; 4(4):314-9.Valdivia I, Campodónico I, Tapia A, Capetillo M, Espinoza A, Lavín P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril. 2004; 81(3):617-23. https://doi.org/10.1016/j.fertnstert.2003.07.041Wender MC, Edelweiss MI, Campos LS, de Castro JA, Spritzer PM. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause. 2004; 11(4):423-9. https://doi.org/10.1097/01.gme.0000109315.11228.acKenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005; 51(1):21-8. https://doi.org/10.1016/j.maturitas.2005.02.011Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int. 2002; 13(3):241-8. https://doi.org/10.1007/s001980200021Lippuner K, Haenggi W, Birkhaeuser MH, Casez JP, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. J Bone Miner Res. 1997; 12(5):806-12. https://doi.org/10.1359/jbmr.1997.12.5.806Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric. 2002; 5(4):390-8.Morris EP, Denton ER, Robinson J, MacDonald LM, Rymer JM. High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure. Climacteric. 1999; 2(1):13-20. https://doi.org/10.3109/13697139909025558Cagnacci A, Baldassari F, Arangino S, Alessandrini C, Volpe A. Administration of tibolone decreases 24 h heart rate but not blood pressure of post-menopausal women. Maturitas. 2004; 48(2):155-60. https://doi.org/10.1016/j.maturitas.2003.08.011Ostberg JE, Damjanovic T, Dimkovic N, Byrne D, Mikhailidis DP, Prelevic GM. Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. Fertil Steril. 2004; 81(6):1624-31. https://doi.org/10.1016/j.fertnstert.2003.11.033Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women. Gynecol Endocrinol. 2004; 18(5):244-57. https://doi.org/10.1080/09513590410001715207Vassalle C, Cicinelli E, Lello S, Mercuri A, Battaglia D, Maffei S. Effects of menopause and tibolone on different cardiovascular biomarkers in healthy women. Gynecol Endocrinol. 2011; 27(3):163-9. https://doi.org/10.3109/09513590.2010.488770.von Eckardstein A, Schmiddem K, Hövels A, Gülbahçe E, Schuler-Lüttmann S, Elbers J, et al. Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity. Atherosclerosis. 2001; 159(2):433-9. https://doi.org/10.1016/s0021-9150(01)00522-6Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, Garibaldi S, et al. Tibolone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrinol Metab. 2004; 89(9):4594-600. https://doi.org/10.1210/jc.2003-032189.Cicinelli E, Ignarro LJ, Galantino P, Pinto V, Barba B, Schonauer S. Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertil Steril. 2002; 78(3):464-8. https://doi.org/10.1016/s0015-0282(02)03295-8Simoncini T, Genazzani AR. Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells. Mol Cell Endocrinol. 2000; 162(1-2):87-94. https://doi.org/10.1016/s0303-7207(00)00206-9Aguayo-Cerón KA, Morales-González JA, Gutiérrez-Iglesias G, Parra-Barrera A, Jiménez-Zamarripa CA, Ocharán-Hernández ME, et al. Efecto Regulador de Tibolona sobre la Actividad Antiinflamatoria del Macrófago. Revista Mexicana De Ingeniería Biomédica. 2019; 40(3):1-10. https://doi.org/10.17488/RMIB.40.3.1North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012; 19(3):257-71. https://doi.org/10.1097/gme.0b013e31824b970aStuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(11):3975-4011. https://doi.org/10.1210/jc.2015-2236Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas. 2006; 55(3):278-87. https://doi.org/10.1016/j.maturitas.2006.04.012Appt SE, Törmälä R, Franke AA, Mikkola TS, Tikkanen MJ, Ylikorkala O, et al. Soy-tibolone combination - effect on lipids in postmenopausal monkeys and women. Maturitas. 2008; 60(3-4):216-22. https://doi.org/10.1016/j.maturitas.2008.06.003Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab. 1997; 82(6):1752-6. https://doi.org/10.1210/jcem.82.6.3995Register TC, Wagner JD, Zhang L, Hall J, Clarkson TB. Effects of tibolone and conventional hormone replacement therapies on arterial and hepatic cholesterol accumulation and on circulating endothelin-1, vascular cell adhesion molecule-1, and E-selectin in surgically menopausal monkeys. Menopause. 2002; 9(6):411-21. https://doi.org/10.1097/00042192-200211000-00006Stark J, Varbiro S, Sipos M, Tulassay Z, Sara L, Adler I, et al. Antioxidant effect of the active metabolites of tibolone. Gynecol Endocrinol. 2015; 31(1):31-5. https://doi.org/10.3109/09513590.2014.943727Dubey RK, Gillespie DG, Grögli M, Kloosterboer HJ, Imthurn B. Tibolone and its metabolites induce antimitogenesis in human coronary artery smooth muscle cells: role of estrogen, progesterone, and androgen receptors. J Clin Endocrinol Metab. 2004; 89(2):852-9. https://doi.org/10.1210/jc.2003-031272Castelo-Branco C, Casals E, Figueras F, Sanjuan A, Vicente JJ, Balasch J, et al. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause. 1999 Summer; 6(2):92-7.Nathorst-Böös J, Hammar M. Effect on sexual life--a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas. 1997; 26(1):15-20. https://doi.org/10.1016/s0378-5122(96)01069-9Espitia De La Hoz FJ, Marega O, Orozco Gallego H. Manejo farmacológico de la disfunción sexual femenina en la postmenopausia, con tibolona y testosterona. Revista de Sexología. 2016; 5(2):9-18.Nijland EA, Weijmar Schultz WC, Nathorst-Boös J, Helmond FA, Van Lunsen RH, Palacios S, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med. 2008; 5(3):646-56. https://doi.org/10.1111/j.1743-6109.2007.00726.xBaños G, Guarner V, Pérez-Torres I. Sex steroid hormones, cardiovascular diseases and the metabolic syndrome. Cardiovasc Hematol Agents Med Chem. 2011; 9(3):137-46. https://doi.org/10.2174/187152511797037547Kotani K, Sahebkar A, Serban C, Andrica F, Toth PP, Jones SR, et al. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis. 2015; 242(1):87-96. https://doi.org/10.1016/j.atherosclerosis.2015.06.056Parkin DE, Smith D, Al Azzawi F, Lindsay R, Hart DM. Effects of long-term Org OD 14 administration on blood coagulation in climacteric women. Maturitas. 1987; 9(1):95-101. https://doi.org/10.1016/0378-5122(87)90057-0Tax L, Kicovic PM. Clinical profile of Org OD14. Maturitas 1984; 6:196.Yates RW, Richards A, McEwan HP, Coutts JR, Walker ID, Davidson JF. Hormonal and fibrinolytic effects of the synthetic steroid Org OD14 in menopausal women. Maturitas 1984; 6:210.Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007; 92(3):911-8. https://doi.org/10.1210/jc.2006-2207.Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, et al. Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res. 2012; 14(1):R13. https://doi.org/10.1186/bcr3097.Bringer J, Raingeard I, Lefebre P, Renard E. Ménopause. Vers un traitement «a la carte». Ann Endocrinol. 2003; 64:337-44.McKinney KA, Thompson W. A practical guide to prescribing hormone replacement therapy. Drugs. 1998; 56:49-57.Modelska K, Cummings S. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol. 2003; 188(1):286-93. https://doi.org/10.1067/mob.2003.117Franklin José Espitia De La Hoz - 2022https://creativecommons.org/licenses/by-nc-sa/4.0http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3223MenopauseHormonesSexualityEffectivenesSafetyCardiovascular diseasesMenopausiaHormonasSexualidadEfectividadSeguridadEnfermedades CardiovascularesInfluencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusicaInfluence of tibolone on sexual function and cardiovascular safety in postmenopausal womenArtículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlehttp://purl.org/redcol/resource_type/ARTREVPublicationOREORE.xmltext/xml2597https://repositorio.unicartagena.edu.co/bitstreams/cedf69e9-54d6-4e2f-a312-b82dff0daabf/download5e41eb756c7d0940cc4916f2a6e0759cMD5111227/14761oai:repositorio.unicartagena.edu.co:11227/147612024-09-05 15:30:25.069https://creativecommons.org/licenses/by-nc-sa/4.0Franklin José Espitia De La Hoz - 2022metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Influencia de la tibolona en la función sexual y seguridad cardiovascular en la mujer posmenopáusica

Publicaciones similares